AACR Annual Meeting 2020 in San Diego, California
Abstract Control Number: 5425
Title: Improved prognosis of breast cancer patients after combined treastment including autologous fomalin-fixed tumor vaccine (AFTV)
Session Category: Immunology
Session Title: Vaccines
Session Date and Time: Tuesday Apr 28, 2020 9:00 AM - 12:30 PM
Location: San Diego Convention Center, Exhibit Halls A-F, Poster Section 51
Poster Board Number: 20
Permanent Abstract Number: 4580 [Place this number on your poster board]
(INTRODUCTION) From 2004, we started to use autologous formalin-fixed tumor vaccine (AFTV) as an adjuvant therapy including chemotherapy, radiation and hormone therapy. Now we investigated the prognosis, and report it.
(CASES) Six hundred and five cases of breast cancer was followed up. One hundred and forty nine cases (Group A) used AFTV (stage 0: 4 cases, stage I: 18 cases, stage II: 71 cases, stage III: 49 cases, stage IV: 7 cases), while four hundred and fifty six cases (Group B) was not used AFTV (stage 0: 61 cases, stage I: 188 cases, stage II: 159 cases, stage III: 31 cases, stage IV: 17cases)
(RESULT) The five-year survival rate of stage 0, I, IIA was not significantly different between Group A and Group B. On the other hand, 5 yrs survival rate of group A (stage IIB, IIIC, IV) was better than Group B. Especially the 5ys rate of stage IIIC+IV Group A (68%) was better than Group B (43%) (p = 0.019).
(DISCUSSION) Whether or not to use AFTV post operatively was depended on the patient and family. At present, evidence level is low, but AFTV group showed prolonged better survival and far better QOL.
(CONCLUSION) The adverse effect of AFTV was rare, therefore it was possible to keep better QOL. AFTV is worth to consider larger scale randomized trial.
